In 2018, Green Shield Canada launched its pilot Biosimilar Transition Program, through 3 plan sponsors, under which patients already receiving biologics were switched to biosimilars. Now that the pilot is complete, the payer is calling the program a success.
In 2016, not-for-profit health benefits company Green Shield Canada (GSC) started to give biosimilars preferred product listings on its formularies, covering reference biologics only in exceptional circumstances for patients who were new to biologic therapy. Then, in 2018, GSC launched a pilot Biosimilar Transition Program, through 3 plan sponsors, under which patients already receiving biologics were switched to biosimilars. Now that the pilot is complete, the payer is calling the program a success.
Patients who were members of the 3 sponsored plans and who were receiving reference infliximab or etanercept therapy were sent letters explaining the pilot program and detailing 2 available options. First, patients could proceed with the one-time switch to biosimilar infliximab or etanercept after discussing it with their prescriber. Second, they could continue to receive their originator biologic and pay the difference in cost between the 2 drugs out-of-pocket.
In total, 41% of members opted to switch to a biosimilar, while 26% chose to remain on the originator product and pay the difference in cost. Another 9% were approved to continue on the originator product after providing clinical justification, while 3% changed to a different treatment entirely for reasons unrelated to the program (the final 21% of patients had not yet submitted a claim at the time of the pilot’s conclusion). GSC’s analysis shows an average savings of $8500 ($6395 USD) per member per year under the program.
GSC notes that, while it originally launched the pilot with the goal of a 60-day timeline to the switch, it amended that goal to 90 days based on feedback from plan sponsors.
It also notes that it partnered with HealthForward, a payer service provider that has dedicated care-coordinator nurses who follow a case management process to provide patients with the assistance that they need. The nurses ensured that there was contact with the patient at 1 month, 3 months, and 6 months to address any issues or answer questions, and HealthForward provided a dedicated phone line for patient support.
GSC says that there were no unexpected questions or concerns during the pilot; most patients were receptive to the switch, and some had even considered switching to a biosimilar prior to the pilot program’s commencement.
Questions asked by patients included the rationale for the change, the cost difference between the products, the efficacy of the biosimilar, and next steps for switching. Among patients who had concerns about the efficacy of the biosimilar, “Their concerns were satisfactorily addressed by the HealthForward care-coordinator nurses,” says GSC in a statement on the program.
On the heels of the successful pilot, GSC is opening the program to any plan sponsor who wants to take part.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.